LPS-neutralizing peptides reduce outer membrane vesicle-induced inflammatory responses.


Journal

Biochimica et biophysica acta. Molecular and cell biology of lipids
ISSN: 1879-2618
Titre abrégé: Biochim Biophys Acta Mol Cell Biol Lipids
Pays: Netherlands
ID NLM: 101731727

Informations de publication

Date de publication:
10 2019
Historique:
received: 13 11 2018
revised: 25 04 2019
accepted: 30 05 2019
pubmed: 5 6 2019
medline: 7 3 2020
entrez: 5 6 2019
Statut: ppublish

Résumé

Outer membrane vesicles (OMVs) are secreted by Gram-negative bacteria and induce a stronger inflammatory response than pure LPS. After endocytosis of OMVs by macrophages, lipopolysaccharide (LPS) is released from early endosomes to activate its intracellular receptors followed by non-canonical inflammasome activation and pyroptosis, which are critically involved in sepsis development. Previously, we could show that the synthetic anti-endotoxin peptide Pep19-2.5 neutralizes inflammatory responses induced by intracellular LPS. Here, we aimed to investigate whether Pep19-2.5 is able to suppress cytoplasmic LPS-induced inflammation under more physiological conditions by using OMVs which naturally transfer LPS to the cytosol. Isothermal titration calorimetry revealed an exothermic reaction between Pep19-2.5 and Escherichia coli OMVs and the Limulus Amebocyte Lysate assay indicated a strong endotoxin blocking activity. In THP-1 macrophages and primary human macrophages Pep19-2.5 and polymyxin B reduced interleukin (IL)-1β and tumor necrosis factor (TNF) release as well as pyroptosis induced by OMVs, while the Toll-like receptor 4 signaling inhibitor TAK-242 suppressed OMV-induced TNF and IL-1β secretion, but not pyroptosis. Internalization of Pep19-2.5 was at least partially mediated by the P2X7 receptor in macrophages but not in monocytes. Additionally, a cell-dependent difference in the neutralization efficiency of Pep19-2.5 became evident in macrophages and monocytes, indicating a critical role for peptide-mediated IL-1β secretion via the P2X7 receptor. In conclusion, we provide evidence that LPS-neutralizing peptides inhibit OMV-induced activation of the inflammasome/IL-1 axis and give new insights into the mechanism of peptide-mediated neutralization of cytoplasmic LPS suggesting an essential and cell-type specific role for the P2X7 receptor.

Identifiants

pubmed: 31163264
pii: S1388-1981(19)30092-7
doi: 10.1016/j.bbalip.2019.05.018
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Lipopolysaccharides 0
Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1503-1513

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Anja Pfalzgraff (A)

Institute of Pharmacy (Pharmacology and Toxicology), Freie Universität Berlin, Berlin, Germany.

Wilmar Correa (W)

Biophysics, Research Center Borstel, Borstel, Germany.

Lena Heinbockel (L)

Institut für Hygiene und Umwelt, Hamburg, Germany.

Andra B Schromm (AB)

Immunobiophysics, Research Center Borstel, Borstel, Germany.

Charlotte Lübow (C)

Institute of Pharmacy (Pharmacology and Toxicology), Freie Universität Berlin, Berlin, Germany; Pharmaceutical Institute, Section Pharmacology and Toxicology, University of Bonn, Germany.

Nicolas Gisch (N)

Bioanalytical Chemistry, Research Center Borstel, Borstel, Germany.

Guillermo Martinez-de-Tejada (G)

Department of Microbiology and Parasitology, Universidad de Navarra, Pamplona, Spain.

Klaus Brandenburg (K)

Brandenburg Antiinfektiva GmbH, Borstel, Germany.

Günther Weindl (G)

Institute of Pharmacy (Pharmacology and Toxicology), Freie Universität Berlin, Berlin, Germany; Pharmaceutical Institute, Section Pharmacology and Toxicology, University of Bonn, Germany. Electronic address: g.weindl@uni-bonn.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH